Reimbursement FAQs: SCIG Prescription Benefit and Vial Size

Addressing questions regarding reimbursement for subcutaneous immune globulin in patients with primary immunodeficiency.
The Drug Shortage Crisis

The drug shortage crisis has been referred to as “a tsunami of medical risk,” and there is no sign that the problem will disappear in the near future.
Reimbursement FAQs: IVIG Access, Specialty Tiers, Drug Shortages and More

Several advocacy groups are focusing their efforts on reimbursement issues that they believe threaten patients’ access to care.
Immune Globulin Reimbursement

A high-cost therapy coupled with a complex and evolving reimbursement model has created what some are calling a healthcare crisis for tens of thousands of chronically ill patients.
Reimbursement FAQs: Patient Affordability Programs

Some commonly held misunderstandings about reimbursement are clarified, including reimbursement for IVIG, SCIG, affordability and assistance.
Reimbursement FAQs: SCIG and Vaccines

Clearing up common misunderstandings about reimbursement rates for subcutaneous immune globulin therapy and vaccine costs.
IVIG: The Evolution of the Manufacturing Process

Modifications in the steps and ingredients of the manufacturing process of immune globulin have changed the world of immune therapy.
New Transparency Reporting Guidelines Affecting Physicians

The healthcare reform laws include new strict reporting guidelines for the medical industry, and physicians need to ensure that what is reported is correct to protect their practice.
Risk Evaluation and Mitigation Strategies: An Update

The FDA’s new strategy to ensure that the safety of certain drugs outweighs the risks they potentially pose to patients continues to evolve as the healthcare industry takes an active role in current and future REMS requirements.
Reimbursement FAQs: Date of Service Billing, Billing Codes, Least Costly Alternatives and More

Examining issues regarding SCIG billing, coding and Medicare claims, along with questions about certification of homebound patients and products with new reimbursement codes.